Brooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer Study

Loading...
Loading...
  • Brooklyn ImmunoTherapeutics Inc BTX has announced results from the INSPIRE Phase 2 trial of IRX-2 in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity.
  • The study's primary endpoint was to estimate 2-year Event-Free Survival (EFS) with key secondary endpoints of Overall Survival (OS) and safety of IRX-2. 
  • 150 patients were enrolled in the study. At two years of follow-up in the intention-to-treat (n=105) population, the median EFS was 48.3 months and was not reached in the control arm (Hazard Ratio 1.10).
  • In key pre-specified subgroups, outcomes favored IRX-2. 
  • Patients in these subgroups were less likely to experience an EFS event in the IRX-2 arm compared to the control. 
  • Trends in EFS rates at two years of follow-up in patients with the later-stage disease were 57.2 vs. 49.4 in favor of IRX-2. 
  • In patients that did not receive chemotherapy (radiation only) as part of adjuvant treatment, the EFS was 76.4 vs. 60.6 in favor of IRX-2. 
  • There were no new safety signals observed with IRX-2. Adverse events related to study treatment were injection site reactions and fatigue.
  • Price Action: BTX shares are down 4.75% at $0.50 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...